HOME >> BIOLOGY >> NEWS
Human Genome Sciences announces the discovery of a novel immune stimulant

und to be a specific B cell stimulant in such tests. As an extension of this program, HGS scientists discovered and prepared the products of about 14,000 newly discovered human genes believed to be involved in cell to cell signaling. These proteins are currently being evaluated in high throughput screens designed to identify new drug candidates that address unmet medical needs.

"The discovery of BLyS and its potential medical application is a milestone for immunology and medicine," said William Haseltine, Ph.D., Chairman and Chief Executive Officer of Human Genome Sciences. "This discovery helps us to understand how the body fights infection and how vaccines work. It is our hope that we can rapidly apply this discovery to the development of new treatments for several serious immune deficiency diseases. We also hope that this discovery will help to overcome the barriers to the creation of successful vaccines for serious infectious disease problems, such as AIDS and Malaria."

Craig Rosen, Ph.D., Senior Vice President Research and Development of HGS said, "The discovery of BLyS represents an exciting application of the integrated set of new genomic technologies that we have developed at HGS over the past three years. We believe that many important new drugs will result from the systematic study of genes and proteins that control cell to cell communication. I am very pleased that our human gene discovery efforts, coupled with our high-throughput systems, resulted in the discovery of this missing component of the immune system. I view this success as validation of a new and fundamentally different approach to the discovery of medical uses of human genes."

The authors of the paper published by Science include: Paul A. Moore, Ph.D.; Ornella Belvedere, M.D.; Amy Orr; Krystyna Pieri; David W. LaFleur; Ping Feng, Ph.D.; Daniel Soppet, Ph.D.; Meghan Charters; Reiner L. Gentz, Ph.D.; David Parmelee, Ph.D.; Yuling Li; Olga Galperina; Judith G. Giri, Ph.D.; Vi
'"/>

Contact: Kate de Santis
Kate_de_Santis@hgsi.com
301-251-6003
Human Genome Sciences, Inc.
9-Jul-1999


Page: 1 2 3 4

Related biology news :

1. Human chromosome 5 final sequence analysis released to public
2. Humans march to a faster genetic drummer than primates, UC Riverside research says
3. Applied Mathematical Models in Human Physiology
4. Human health risks in space flight focus of research internships
5. Human periodontal ligament stem cells isolated for the first time
6. Organization for Human Brain Mapping 2004 Annual Meeting
7. 20 May AAAS lecture: Computers that Respond to Human Emotion
8. Human brain works heavy statistics learning language
9. New Woods Hole Center for Oceans and Human Health established
10. European Society of Human Reproduction and Embryology conference - June 2004
11. Human genome-wide RNAi library for biotech and pharma research

Post Your Comments:
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
Cached News: